For the quarter ending 2025-09-30, SKYE had -$5,397,165 decrease in cash & cash equivalents over the period. -$13,364,375 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -12,754,660 | -28,728,191 |
| Depreciation and amortization | 178,898 | 364,445 |
| Stock-based compensation expense | 1,914,136 | 4,235,018 |
| Amortization of debt discount | 0 | 0 |
| Gains from asset sales | 91,400 | 89,363 |
| Write-down of vendor deposits | 0 | 0 |
| Loss from disposal of assets | 0 | 0 |
| Change in estimate for legal contingency | 0 | - |
| Prepaid expenses | 2,448,499 | 1,061,850 |
| Other current assets | 166,752 | -1,476,121 |
| Other assets | 0 | - |
| Accounts payable | -397,505 | 2,584,507 |
| Accrued interest - legal contingency-Related Party | 0 | 0 |
| Accrued interest - legal contingency-Nonrelated Party | 0 | 0 |
| Accrued payroll liabilities | 52,750 | -246,231 |
| Operating lease liability | -45,695 | -88,050 |
| Other current liabilities | 394,352 | 1,621,927 |
| Net cash used in operating activities | -13,364,375 | -19,931,667 |
| Proceeds from the sale of assets, net of sales costs | 91,400 | 89,363 |
| Purchase of short-term investments, net of maturities | -7,875,810 | 24,747,039 |
| Purchase of property and equipment | 0 | 6,312 |
| Net cash used in investing activities | 7,967,210 | -24,663,988 |
| Purchase under employee stock purchase plan | 0 | 18,158 |
| Proceeds from the issuance of common stock and warrants, net of equity issuance costs of 0 and 6,434,447, respectively | 0 | 0 |
| Net cash provided by financing activities | 0 | 18,158 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -5,397,165 | -44,577,497 |
| Cash and cash equivalents at beginning of period | 68,415,741 | - |
| Cash and cash equivalents at end of period | 18,441,079 | - |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)